Standard Robots and Qingdao Haier-Medical Co., Ltd. (Hereinafter referred to as Haier-Medical) signed a strategic cooperation agreement. As a result, they can now cooperate at different levels in critical fields related to applying robots in innovative medical scenarios.

Standard Robots is a company that specializes in the R&D of industrial-level mobile robots. As a leader in the AMR industry, Standard Robots has achieved full coverage of its independent R&D for core technologies, such as robot positioning and navigation algorithms, operations and scheduling systems, and controllers. Its products have been used in China, the United States, Japan, Europe, the Middle East, Southeast Asia, and other countries and regions. In addition, they are employed in many industries related to 3C products, medical and pharmaceutical products, semiconductor products, PV, lithium-ion batteries, panels, and automotive parts.

Haier-Medical is the world's leading provider of integrated IoT biosecurity solutions, which have been applied in more than 120 countries and regions around the globe, securing tens of thousands of domestic hospitals, biotechnology enterprises, universities, and research institutions, disease control centers, plasma stations, testing agencies, and other end-users in the medical and health fields.

This strategic cooperation will see Haier-Medical introducing Standard Robots artificial intelligence technology into its blood component preparation and drug management scenarios to promote the application of robots in intelligent medical methods and accelerate the convenient digital upgrades to IoT biosafety digital medical solutions.

Standard Robots CEO Wang Yong Kun said, "Standard Robots is now connected to Haier-Medical's smart medical scenarios and will bring safer, more accurate, and efficient solutions to the medical industry, which will contribute to the digitalization of China's medical scenario management."

Chen Haitao, deputy manager of Haier-Medical, said, "Standard Robots and Haier-Medical bring their technical advantages to the table to accelerate intelligent, digital, and unmanned development of metropolitan blood and drug management to promote the new infrastructure of digital healthcare further while reducing costs and improving efficiency." 

Standing at the new starting point of the 14th Five-Year Plan, it is an inevitable trend that the medical industry will upgrade from manufacturing to intelligent manufacturing. As leaders in their respective fields, the two companies have complementary solid advantages and a reasonable basis for cooperation. This comprehensive strategic cooperation will also add a new impetus for Standard Robots to promote the construction of a healthy China. In the future, both parties will continue to expand their cooperation and create high-quality intelligent medical services.